| Released | Contributor | Author | Title | Pages | Price |
| 9-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Comprehensive Rating Report | 48 |
$99 |
| 7-Dec-2009 | Reuters Investment Profile |
N/A
| Neurologix Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 7-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for NRGX | 13 |
$25 |
| 4-Dec-2009 | Pechala's Reports | Lubomir Pechala | NEUROLOGIX INC (NRGX=US) 2-weeks forecast | 1 |
$10 |
| 4-Dec-2009 | Pechala's Reports | Frantisek Pechala | NEUROLOGIX INC (NRGX=US) 12-months forecast | 1 |
$15 |
| 3-Dec-2009 | Roth Capital Partners, Inc. | Scott R. Henry CFA, Andrew Vaino PhD | Neurologix Completes Surgeries For Phase 2 Parkinson's Disease Study | 3 |
$10 |
| 3-Dec-2009 | Roth Capital Partners, Inc. | Research Department | Morning Call Summary | 8 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Neurologix, Inc. | 40 |
$65 |
| 13-Nov-2009 | Roth Capital Partners, Inc. | Research Department | Morning Call Summary | 21 |
$75 |
| 12-Nov-2009 | Roth Capital Partners, Inc. | Scott R. Henry CFA, Andrew Vaino | NRGX Q3 Earnings Close To Expectations, Looking To Clinical Data In H1 2010 | 6 |
$25 |
0.67% Nasdaq 0.00%
Research Reports
